Neoadjuvant T-VEC May Reduce Recurrence in Operable Melanoma

Published: Thursday, Jun 06, 2019
Reinhard Dummer, MD

Reinhard Dummer, MD

Neoadjuvant treatment with the oncolytic immunotherapeutic agent talimogene laherparepvec (T-VEC; Imlygic) led to significant improvement in 1-year recurrence-free survival (RFS) for patients with resectable advanced melanoma compared with surgery alone, a randomized trial showed.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x